Evidence map›Paper›PMID 24391889›Full record

ArticlePloS one2013

Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.

Lillian Seu, Gabriel M Ortiz, Lorrie Epling, Elizabeth Sinclair, Louise A Swainson, Urmila D Bajpai, Yong Huang, Steven G Deeks, Peter W Hunt, Jeffrey N Martin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lillian SeuDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmacy, University of California San Francisco, San Francisco, California, United States of America ; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Gabriel M OrtizDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Lorrie EplingDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Core Immunology Laboratory, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Elizabeth SinclairDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Core Immunology Laboratory, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Louise A SwainsonDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Urmila D BajpaiDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Division of Rheumatology, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Yong HuangDepartment of Bioengineering and Therapeutic Sciences, Department of Pharmacy, University of California San Francisco, San Francisco, California, United States of America.
Steven G DeeksPositive Health Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Peter W HuntPositive Health Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Jeffrey N MartinPositive Health Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Joseph M McCuneDivision of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
San Francisco General Hospital · USUniversity of California, San Francisco · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Specimen Acquisition and Distribution CoreP01AI076174 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL · 2008 to 2012
$10.9M
BIOLOGY OF INFECTIOUS DISEASES TRAINING PROGRAMT32AI007641 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY · 2000 to 2026
$6.9M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
HIV EFFECTS ON THE CENTRAL HEMATOLYMPHOID SYSTEMR37AI040312 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCUNE, JOSEPH M · 2000 to 2010
$5.0M
NIH Director's Pioneer Award (RMI)DP1OD000329 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCUNE, JOSEPH M · 2004 to 2008
$4.2M
The impact of early antiretroviral therapy on HIV persistence and inflammationR01AI087145 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2009 to 2010
$1.6M
Preventing the Establishment of Enfuvirtide-resistance in the Latent ReservoirK24AI069994 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2007 to 2016
$1.5M
NCRR NIH HHS UL1 RR024131NIAID NIH HHS 2T32AI007641NIAID NIH HHS AI-76174NIAID NIH HHS K24 AI069994NIAID NIH HHS K24AI069994NIAID NIH HHS P01 AI076174NIAID NIH HHS P0 AI27763NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI087145NIAID NIH HHS R24 AI067039NIAID NIH HHS R37 AI040312NIAID NIH HHS R37 AI40312NIAID NIH HHS T32 AI007641NIAID NIH HHS T32 AI060530NIAID NIH HHS U01 AI43641NIH HHS DP1 OD000329NIH HHS DPI OD00329
6 · The paper itself

Abstract

HIV-mediated immune dysfunction may influence CD4(+) T cell recovery during suppressive antiretroviral therapy (ART). We analyzed cellular biomarkers of immunological inflammation, maturation, and senescence in HIV-infected subjects on early suppressive ART. We performed longitudinal analyses of peripheral immunological biomarkers of subjects on suppressive ART (n = 24) from early treatment (median 6.4 months, interquartile range [IQR] 4.8-13.9 months) to 1-2 years of follow-up (median 19.8 months, IQR 18.3-24.6 months). We performed multivariate regression to determine which biomarkers were associated with and/or predictive of CD4(+) T cell recovery. After adjusting for the pre-ART CD4(+) T cell count, age, proximal CD4(+) T cell count, and length of ART medication, the percentage of CD27(+)CD8(+) T cells remained significantly associated with the CD4(+) T cell recovery rate (β = 0.092 cells/ul/month, P = 0.028). In HIV-infected subjects starting suppressive ART, patients with the highest percentage of CD8(+) T cells expressing CD27 had the greatest rate of CD4(+) T cell recovery.

Indexed as

Antiretroviral Therapy, Highly ActiveAdultBiomarkersCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFlow CytometryFollow-Up StudiesHIV-1HIV InfectionsHumansLongitudinal StudiesMiddle AgedRisk FactorsRNA, ViralTumor Necrosis Factor Receptor Superfamily, Member 7Viral LoadBiomarkersRNA, ViralTumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID24391889
PMCPMC3877182
OpenAlexW1975268934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.